Lydia D. Foster

TL;DR: The trial showed similar safety outcomes and no significant difference in functional independence with endovascular therapy after intravenous t-PA, as compared with intravenoust-PA alone.

TL;DR: Delays in time to angiographic reperfusion lead to a decreased likelihood of good clinical outcome in patients after moderate to severe stroke, and this association was validated in a preplanned analysis of data from the IMS III trial.

TL;DR: The data from the largest endovascular trial to date suggest that collaterals are an important consideration in future trial design, and more robust collateral grade was associated with better recanalization, reperfusion, and subsequent better clinical outcomes.

TL;DR: B baseline computed tomographic angiography was used to analyze imaging and clinical end points in an Interventional Management of Stroke III cohort to identify patients who would benefit from endovascular stroke therapy and carotid T- or L-type and tandem ICA and M1 occlusions showed greater recanalization and a trend toward better outcome with endov vascular treatment.

TL;DR: The primary result showed that further study of the efficacy of deferoxamine mesylate with anticipation that the drug would significantly improve the chance of good clinical outcome would be futile and the drug merits investigation in a phase 3 trial.